1704-1705 / 2437
KIARA trial
Multicenter, non-randomised, open-label, single agent, phase II study to determine the clinical
benefit of T-DM1 in HER2-positive metastatic breast cancer patients with brain metastasis
PIs:
M. Preusser & E. de Azambuja